by Steven D. Targum, MD, and David Mischoulon, MD, PhD

Dr. Targum is an executive-in-residence at Oxford BioScience Partners and on the faculty of the Department of Psychiatry at the Massachusetts General Hospital. Dr. Targum is chief medical officer at BrainCells Inc. and chief medical advisor to Prana Biotechnology Ltd. Dr. Targum is on the editorial board of Psychiatry 2009. Dr. Mischoulon is the director of research for the Depression Clinical and Research Program at Massachussetts General Hospital and Associate Professor of psychiatry at Havard Medical School in Boston, Massachussetts.

Psychiatry (Edgemont) 2009;6(9):46–48

Popularity: unranked [?]

Related posts:

1. Current Status of Hypnotic Prescribing Habits in the United States
2. Treatment of Depression: Antidepressant Monotherapy and Combination Therapy